TABLE 2.
Summary of statistical analysis
| Fig. # | Analysis type and animal numbers |
|---|---|
| 1A |
Unpaired two‐tailed t‐test: t = 1.53, df = 10, p = 0.158 IBA291: 87.3 ± 10.6 (mean ± SD) IBA340: 75.7 ± 15.2 (mean ± SD) |
| 1B |
Unpaired two‐tailed t‐test: t = 0.16, df = 10, p = 0.875 IBA291: 80.2 ± 18.1 (mean ± SD) IBA340: 78.6 ± 15.3 (mean ± SD) |
| 2A |
One‐way ANOVA: F (2,19) = 11.6, p < 0.001. Dunnett's multiple comparisons test: **p = 0.01, ***p < 0.001 versus IBA291. One outlier was removed from IBA291 group IBA291: 49.7 ± 8.3 (mean ± SD) IBA340 (4 mg/kg): 31.8 ± 8.2 (mean ± SD) IBA340 (30 mg/kg): 33.2 ± 6.0 (mean ± SD) |
| 2B |
One‐way ANOVA: F (2,27) = 4.29. Dunnett's multiple comparisons test: *p = 0.019 IBA291: 50.21 ± 14.01 (mean ± SD) IBA340 (4 mg/kg): 47.3 ± 6.2 (mean ± SD) IBA340 (30 mg/kg): 35.6 ± 13.5 (mean ± SD) |
| 3A |
Unpaired two‐tailed t‐test: t = 0.054, df = 13, p = 0.958. One animal was removed from the Galcanezumab group due to error dosing charcoal meal IgG4PAA: 36.6 ± 6.2 (mean ± SD) Galcanezumab (4 mg/kg): 36.8 ± 7.70 (mean ± SD) |
| 3B |
Unpaired two‐tailed t‐test: t = 0.10, df = 18, p = 0.929 IgG4PAA: 38.0 ± 18.2 (mean ± SD) Galcanezumab (30 mg/kg): 38.7 ± 12.1 (mean ± SD) |
| 4 |
Unpaired two‐tailed t‐test: t = 2.84, df = 14, *p = 0.013 vehicle: 48.1 ± 9.3 (mean ± SD) Telcagepant (5 mg/kg): 30.64 ± 14.74 (mean ± SD) |
| 5A |
One‐way ANOVA: F (2,24) = 1.02. p = 0.229 vehicle: 41.2 ± 8.3 (mean ± SD) Atogepant (0.03 mg/kg): 36.1 ± 17.9 (mean ± SD) Atogepant (0.3 mg/kg): 30.0 ± 12.2 (mean ± SD) |
| 5B |
Unpaired two‐tailed t‐test: t = 2.39, df = 15, *p = 0.030. One animal was removed from the Atogepant group due to a dosing issue. vehicle: 41.2 ± 3.7 (mean ± SD) Atogepant (3 mg/kg): 30.6 ± 12.0 (mean ± SD) |
Abbreviations: ANOVA, analysis of variance; IgG, immunoglobulin; SD, standard deviation.